KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $1.3 billion.

  • Vertex Pharmaceuticals' Other Non-Current Liabilities rose 2512.32% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 2512.32%. This contributed to the annual value of $1.3 billion for FY2025, which is 2512.32% up from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $1.3 billion for Q4 2025, which was up 2512.32% from $1.2 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Non-Current Liabilities peaked at $1.3 billion during Q4 2025, and registered a low of $127.2 million during Q3 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $806.4 million (2023), whereas its average is $677.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first plummeted by 5601.14% in 2021, then soared by 58341.19% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $303.3 million in 2021, then skyrocketed by 126.11% to $685.8 million in 2022, then increased by 27.98% to $877.7 million in 2023, then grew by 15.6% to $1.0 billion in 2024, then grew by 25.12% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.2 billion for Q3 2025, and $1.2 billion during Q2 2025.